Effects of CLDN9 on Proliferation of Uterine Corpus Endometrioid Carcinoma Cells
Authors: 
Jiayu Zhang, Pei Kuang, Fujian Wan, Yingjie Zhang, Wenhua Zhang, Xiaoyu ZhangAuthors Info & Claims
Pages 136 - 142
Abstract
Claudin 9 (CLDN9) is a member of the claudin family. CLDN9 is aberrantly expressed in a variety of tumors, but the biological role of CLDN9 in uterine corpus endometrioid carcinoma is unknown. In this study, CLDN9 was analyzed by various public online databases, suggesting that its expression was elevated in uterine corpus endometrioid carcinoma and confirmed by RT-qPCR and Western Blot assays in UCEC cell lines in vitro. In addition, knockdown of CLDN9 expression was shown to inhibit the proliferation of UCEC cells using cck8 and EdU assays. These results provide a theoretical basis for CLDN9 as a potential uterine corpus endometrioid carcinoma marker and a new clinical therapeutic target.
References
[1]
CROSBIE E J, KITSON S J, MCALPINE J N, Endometrial cancer [J]. Lancet, 2022, 399(10333): 1412-28.
[2]
BROOKS R A, FLEMING G F, LASTRA R R, Current recommendations and recent progress in endometrial cancer [J]. CA Cancer J Clin, 2019, 69(4): 258-79.
[3]
MAKKER V, MACKAY H, RAY-COQUARD I, Endometrial cancer [J]. Nat Rev Dis Primers, 2021, 7(1): 88.
[4]
VAN DEN HEERIK A, HOREWEG N, DE BOER S M, Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy [J]. Int J Gynecol Cancer, 2021, 31(4): 594-604.
[5]
LU K H, BROADDUS R R. Endometrial Cancer [J]. N Engl J Med, 2020, 383(21): 2053-64.
[6]
TERZIC M, AIMAGAMBETOVA G, KUNZ J, Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives [J]. Int J Mol Sci, 2021, 22(17).
[7]
PASSARELLO K, KURIAN S, VILLANUEVA V. Endometrial Cancer: An Overview of Pathophysiology, Management, and Care [J]. Semin Oncol Nurs, 2019, 35(2): 157-65.
[8]
MCDONALD M E, BENDER D P. Endometrial Cancer: Obesity, Genetics, and Targeted Agents [J]. Obstet Gynecol Clin North Am, 2019, 46(1): 89-105.
[9]
SUGIMOTO K, CHIBA H. The claudin-transcription factor signaling pathway [J]. Tissue Barriers, 2021, 9(3): 1908109.
[10]
BHAT A A, SYED N, THERACHIYIL L, Claudin-1, A Double-Edged Sword in Cancer [J]. Int J Mol Sci, 2020, 21(2).
[11]
UNGUREANU B S, LUNGULESCU C V, PIRICI D, Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis [J]. Frontiers in oncology, 2021, 11: 643872.
[12]
ENDO Y, SUGIMOTO K, KOBAYASHI M, Claudin‑9 is a novel prognostic biomarker for endometrial cancer [J]. Int J Oncol, 2022, 61(5).
[13]
LIU H, WANG M, LIANG N, Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling [J]. Turk J Gastroenterol, 2019, 30(8): 722-31.
[14]
GONZALEZ-MAGANA A, BLANCO F J. Human PCNA Structure, Function and Interactions [J]. Biomolecules, 2020, 10(4).
[15]
YANG C, ZHANG J, DING M, Ki67 targeted strategies for cancer therapy [J]. Clin Transl Oncol, 2018, 20(5): 570-5.
[16]
BAI H, WANG R, LI Y, Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of Prunella vulgaris L. in Treating Breast Cancer [J]. Evid Based Complement Alternat Med, 2022, 2022: 5481563.
[17]
CANZLER S, HACKERMULLER J. multiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data [J]. BMC Bioinformatics, 2020, 21(1): 561.
[18]
SZKLARCZYK D, GABLE A L, LYON D, STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucleic Acids Res, 2019, 47(D1): D607-D13.
[19]
SZKLARCZYK D, KIRSCH R, KOUTROULI M, The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest [J]. Nucleic Acids Res, 2023, 51(D1): D638-D46.
[20]
CAI Y, WANG B, XU W, Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine [J]. Curr Med Chem, 2021, 28(42): 8755-81.
[21]
URICK M E, BELL D W. Clinical actionability of molecular targets in endometrial cancer [J]. Nat Rev Cancer, 2019, 19(9): 510-21.
[22]
NEES L K, HEUBLEIN S, STEINMACHER S, Endometrial hyperplasia as a risk factor of endometrial cancer [J]. Arch Gynecol Obstet, 2022, 306(2): 407-21.
[23]
DOHERTY M T, SANNI O B, COLEMAN H G, Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis [J]. PLoS One, 2020, 15(4): e0232231.
[24]
YANG J, LEE S H, GODDARD M E, GCTA: a tool for genome-wide complex trait analysis [J]. Am J Hum Genet, 2011, 88(1): 76-82.
[25]
VERMIJ L, SMIT V, NOUT R, Incorporation of molecular characteristics into endometrial cancer management [J]. Histopathology, 2020, 76(1): 52-63.
Index Terms
- Effects of CLDN9 on Proliferation of Uterine Corpus Endometrioid Carcinoma Cells
Recommendations
Effects of FLVCR1 on Proliferation and Migration of Hepatocellular Carcinoma Cells
ICBBT '22: Proceedings of the 14th International Conference on Bioinformatics and Biomedical TechnologyStudies have found that feline leukemia virus subgroup C receptor 1 (FLVCR1) is dysregulated in a variety of tumor tissues. However, with rare studies on FLVCR1 in hepatocellular carcinoma (HCC), the mechanism underneath is still unclear. In this study, ...
Transcription factor NFE2L3 promotes the proliferation of esophageal squamous cell carcinoma cells and causes radiotherapy resistance by regulating IL-6
Highlights- NFE2L3 can affect the radiosensitivity of ESCC cells.
- NFE2L3 plays a role ...
Abstract ObjectiveTo scrutinize the impact of overexpression and interference of NFE2L3 on radiosensitivity of esophageal squamous cell carcinoma cells (ESCC) and its downstream mechanism and to assess whether NFE2L3 expression ...
Inhibitory Effect of Ursolic Acid on Proliferation and Migration of Renal Carcinoma Cells and Its Mechanism
Background. Renal carcinoma is one of the most common malignant tumors in the urinary system. Autophagy can be both activated and inhibited in renal carcinoma, and it plays a double-edged role in the development of renal carcinoma. In the early stage of ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
May 2023
313 pages
ISBN:9798400700385
DOI:10.1145/3608164
Copyright © 2023 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 07 November 2023
Check for updates
Author Tag
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ICBBT 2023
ICBBT 2023: 2023 15th International Conference on Bioinformatics and Biomedical Technology
May 26 - 28, 2023
Xi'an, China
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 17Total Downloads
- Downloads (Last 12 months)17
- Downloads (Last 6 weeks)0
Reflects downloads up to 18 Nov 2024
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format